The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.

The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Athira Pharma has been on a bumpy road in recent years, and now the company is restructuring and shedding weight to try to ...

The millage increase is needed because the overall cost of operating the county has increased, inflation is up and the portion the county pays for its part of health insurance for its employees is ...

Lincoln Equities Group debuted its speculative project 800 feet from the city's Global Container Marine Terminal, while Phase ...

The first phase of what eventually will be the country’s largest truck stop is set to open Oct. 1 off Interstate 90 in West ...

The first phase of the Jammu and Kashmir polls saw men outnumbering women in casting votes by over 4.79 percentage points, ...

NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...

The next morning, Sept. 16, Hawaiian Volcano Observatory scientists on a helicopter overflight confirmed that a small ...

Plus: LiquidStack raises $20 Million in Series B extension investment, HEST Investments secures $1.8 million SPV investment ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...